Atosiban
Atosiban is a peptide analogue of oxytocin but with oxytocin properties. It has been investigated by IV-inf as a tocolytic in the management of premature labor, but there is some concern about adverse effects on the fetus.
Primary Characteristics
It is of Synthetic origin.
Molecular Weight: 994.2 · Non-proprietary name: Atosiban.
Pharmacokinetics
Distribution: Atosiban has a volume of distribution is 18.3±6.8litre. plasma protein binding is 46-48%.
Advertisement
Indications
Atosiban is primarily indicated in conditions like Prostate cancer, flare with initial gonadorelin therapy, Uncomplicated premature labor.
Contraindications
Atosiban is contraindicated in conditions like Eclampsia, Intrauterine fetal death, Antepartum haemorrhage, Placenta previa, Nausea and vomiting of terminal illness, Motor TICS and adjunctive treatment in chorea, Autoimmune conditions, Dermatological conditions caused or aggravated by sunlight.
Dosage
None recorded.
Drug Interactions
None recorded.
Side Effects
Atosiban is known to cause more or less tolerable side effects which are usually transient. These include Dizziness, Fever, Headache, Hot flushes, Hyperglycemia, Injection site reactions, Insomnia, Nausea, Rashes , Tachycardia, Vomiting .
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.22.1.1 — Oxytocics